Gilead Appoints Christi L. Shaw as Chief Executive Officer of Kite
July 11 2019 - 4:30PM
Business Wire
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that
Christi L. Shaw will join the company as Chief Executive Officer of
Kite, a Gilead Company, and will become a member of Gilead’s senior
leadership team.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190711005777/en/
Ms. Shaw is a renowned leader with deep experience providing
commercial, financial, strategic, medical and operations leadership
across the biopharmaceutical industry. Ms. Shaw currently serves as
Senior Vice President of Eli Lilly &. Co., and President of
Lilly Bio-Medicines. She also serves as a board member of both
Avantor, Inc. and the Biotechnology Industry Organization (BIO),
and as an advisor to the Healthcare Businesswomen’s
Association.
Prior to joining Lilly, Ms. Shaw most recently served as U.S.
Country Head and President of Novartis Corp. and North American
Head of Novartis Oncology. She earned a BA in Business
Administration from Iowa State University and an MBA from the
University of Wisconsin.
“We conducted an extensive search for a new leader at Kite and
we believe that Christi’s unique set of skills will allow us to
continue to build on our leadership position in cell therapy,” said
Daniel O’Day, Chairman and Chief Executive Officer of Gilead.
“Christi’s vast experience across complex therapeutic areas, and
particularly in oncology, will serve Kite very well. She is clearly
a leader who will bring teams and individuals together and I am
confident she will build upon the entrepreneurial spirit at Kite as
we seek to help more people with cancer around the world.”
“Kite’s vision of transformational drug development – and of
curing cancer – is one that I am extremely passionate about,” said
Ms. Shaw. “I look forward to working with the many talented
individuals in this organization, as we change the way cancer is
treated and bring forward important, life-saving therapies.”
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in
Santa Monica, California. Kite is engaged in the development of
innovative cancer immunotherapies. The company is focused on
chimeric antigen receptor and T cell receptor engineered cell
therapies. For more information on Kite, please visit
www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
For more information on Kite, please visit the
company’s website at www.kitepharma.com. Learn more about Gilead at
www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005777/en/
Sung Lee, Investors (650) 524-7792
Shant Salakian, Media (424) 384-1841
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024